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Despite the publication of numerous studies, including some multicentered randomized controlled trials, there continues to be
vigorous debate regarding the optimal management of early stage endometrial cancer, including the extent of surgery and the role
of adjuvant chemotherapy and radiation. Resolving these questions has become increasingly important in view of the increase of
endometrial cancer, related to the aging population and the alarming incidence of obesity. Furthermore, there are more surgical
challenges encountered when operating on elderly patients or on patients with increased BMI and the associated comorbidities,
such as diabetes, hypertension, heart disease, and pulmonary dysfunction. This paper will focus on the advantages of minimally
invasive surgery, the value of lymphadenectomy including sentinel lymph node mapping, and some of the current controversies
surrounding adjuvant chemotherapy and radiation.
1.Introduction
The reader should be aware that most studies predate the
present staging system (Table 1). Women with endometrial
adenocarcinoma typically present with vaginal bleeding that
prompts a pelvic examination and endometrial biopsy. The
biopsy gives a general indication of the histology and grade.
Endometrioid histology accounts for most cases (80%) and
is graded from 1 to 3 depending on the degree to which
normal architecture is lost and the extent of nuclear atypia.
The remaining 20% of cases consist of nonendometrioid
histology such as serous and clear cell histology, which
are considered high grade because they are generally more
aggressive and less predictable, with up to 50% lymph node
metastases.
Unless patients are very poor surgical candidates, most
physicians will initiate treatment with surgery. Typically the
surgery includes hysterectomy and bilateral salpingoopho-
rectomy, with or without lymphadenectomy, performed
via traditional laparotomy, conventional laparoscopy, or
robotic-assisted laparoscopy. Following surgery, the need for
adjuvant treatment will be based on the ﬁnal pathologic
grade and histology, that can diﬀer from the preoperative
biopsy in up to 30% of the cases. The surgical specimen will
in addition provide information about the depth of invasion,
lymphovascular space invasion (LVSI), and tumor size, as
wellastheextentofextrauterinediseaseiflymphadenectomy
or peritoneal biopsies are performed. The patient’s risk of
recurrence can then be estimated based on these pathologic
factors (Table 2) leading to the risk-beneﬁt analysis of
adjuvant treatment, whether this adjuvant therapy will be in
the form of radiation (vaginal brachytherapy or teletherapy),
chemotherapy, or both [1]. A small proportion of patients
are found to have advanced stage disease at presentation
with pelvic/para-aortic lymph node or intra-abdominal
metastases.Thesepatientswillrequiremultimodaltreatment
with chemotherapy and radiation and tend to have a poor
prognosis.
For early stage patients, developing the best management
plan involves a ﬁne balance between the risk of recurrence
resulting from undertreatment and the risk of complications
from overtreatment. Overtreatment can occur both from
surgical interventions such as lymphadenectomy and adju-
vant therapies such as radiation and chemotherapy.2 Obstetrics and Gynecology International
Table 1: Comparison of 1988 and 2010 surgical staging system for
endometrial cancer.
Extent of tumor involvement 1988 staging 2010 staging
Endometrium only 1A IA
Myometrium < 1/2 IB IA
Myometrium > 1/2 IC IB
Cervix mucosa IIA —
Cervix stroma IIB II
Uterine serosa/adnexa IIIA IIIA
Vagina/parametrial IIIB IIIB
Positive lymph nodes pelvic IIIC IIIC1
Positive lymph nodes periaortic IIIC IIIC2
Bladder or bowel mucosa IVA IVA
Distant metastases IVB IVB
Table 2: Risk of lymph node involvement and 5-year progression
free survival based on depth of invasion and grade.
Depth of invasion Grade Risk of LN
involvement 5-year PFS
Superﬁcial (IA) 1 or 2 <3% >95%
Superﬁcial (IA) 3
∼10% ∼80% Less than 50% (IB) 1 or 2
Greater than 50% (1C) 1 or 2
Greater than 50% (1C) 3
∼30% ∼50% Cervical involvement (II) any grade
2.SurgicalApproach:TraditionalLaparotomy
versus Conventional Laparoscopy versus
Robotic-AssistedLaparoscopy
The traditional surgical technique for endometrial carci-
noma has involved a laparotomy, either through a low trans-
verse or a midline abdominal incision. With the increasing
incidence of obesity and associated medical conditions this
choice of surgical approach has come into question, in view
of the prolonged recovery and increased wound compli-
cations. Following the ﬁrst laparoscopic pelvic/para-aortic
lymph node dissection for gynecologic cancer, reported
by Querleu et al. in 1992 [2], there has been increasing
utilization of the laparoscopic approach for endometrial
cancerstaging.Thisculminatedinseveralrecentrandomized
controlled trials comparing laparotomy to laparoscopy for
surgical staging of endometrial carcinoma. The ﬁrst study
organized by the GOG (LAP2) randomized patients with
clinical stage I-IIA endometrial cancer to hysterectomy with
complete pelvic and para-aortic lymph node dissection by
either laparoscopy or laparotomy [3]. The study enrolled
1696 patients to the laparoscopy group and 920 to the
laparotomy group. Although the preliminary outcome data
that showed similar disease-free and overall survival has
just been presented as an oral communication at the SGO
in 2010, complete information on surgical outcome data
has already been published [4]. There was no signiﬁcant
diﬀerence in node positivity rate (9%), positive cytology
rate, or detection of advanced stage disease (17%). The
laparoscopy group was found to have an improved safety
proﬁle with fewer postoperative complications (P<0.001),
less antibiotic use (P<0.001), and shorter hospital stay
(P<0.001). Patients in the laparoscopy group also had
higher quality of life scores (P<0.001), with better physical
functioning, better body image, less pain (P<0.001), earlier
resumption of normal activities (P<0.003), and earlier
return to work over the 6 weeks following surgery. These
diﬀerences remained up to 6 months after surgery (P<
0.04). Although this study demonstrated that laparoscopy
was feasible and beneﬁcial, the overall conversion rate from
laparoscopy to laparotomy was as high as 26%, and this
rate increased to 57% in women with a body mass index
(BMI) greater than 40kg/m2. Considering that women with
endometrial carcinoma frequently have a BMI greater than
40, a signiﬁcant proportion of patients would not beneﬁt
from this minimal invasive approach and end up with
a laparotomy with the associated wound infection and
breakdown. The second trial that randomized endometrial
cancer patient to either laparotomy (n = 142) or laparoscopy
(n = 190) was performed in Australia, New Zealand, and
Hong Kong (LACE study) and also showed signiﬁcantly
shorter hospital stay and improved quality of life at both
4 weeks and 6 months [5]. Although this study had a
lower conversion rate (3.6%), surgeons were permitted to
omit lymphadenectomy depending on the BMI and medical
ﬁtness of patients, resulting in only 52% of patient having
dissection of pelvic nodes, para-aortic nodes, or both. A
third randomized trial performed in The Netherlands also
conﬁrmed that a laparoscopic approach provided beneﬁt
with respect to shorter hospital stay, less pain, and quicker
resumption of daily activities, with a conversion rate in The
laparoscopy group of 10.8% [6]. However, the inﬂuence of
lymphadenectomy was not assessed in this study because
lymphadenectomy is not a component of surgery for Stage
I disease in the Netherlands.
A potential enhancement to the traditional laparoscopic
technique has been provided by the creation of a robotic
platform which facilitates minimally invasive procedures.
Theﬁrstreportofrobotic-assistedlaparoscopichysterectomy
was published in 2002 [7]. Since that time the use of
robotic-assisted laparoscopy for endometrial cancer staging
has advanced rapidly, particularly in the United States.
The switch from traditional laparoscopy to robotic-assisted
laparoscopy has been criticized particulary due to the high
cost of the robotic technology. Those who use the robotic
platform argue that the extensive range of motion and three-
dimensional visualization has simpliﬁed the performance of
minimally invasive surgery, thereby minimizing the need for
conversion to laparotomy. The largest published series of
robotic-assisted laparoscopic endometrial cancer staging was
reported in 2011 by Paley et al. [8] .T h es e r i e sc o m p a r e d3 7 7
robotic surgeries for endometrial cancer to 131 laparotomies
performed at the same institution. The major complication
rate was signiﬁcantly less with robotic surgery (20.6%
versus 6.4%), particulary related to wound complications
and infections. This diﬀerence in major complication rate
became even more apparent in the cohort of patients withObstetrics and Gynecology International 3
BMI > 40 (43.5% versus 11.3%). This data is consistent with
the ﬁndings of the LAP2 study where minimally invasive
techniquewasassociatedwithfewercomplications.However,
in this robotic series the total conversion rate to laparotomy
was 3.4%, with a conversion rate of only 5.8% in the 52
morbidly obese patients with a BMI greater than 40. In our
ﬁrst 100 endometrial cancer cases performed robotically, we
had a 6% conversion rate, and all of these conversions were
performed at the end of the robotic surgery by minilaparo-
tomy to remove enlarged uteri that could not be delivered
intact via the lower genital tract [9]. Technical improvements
utilizing a large endobag introduced via the vagina at the
end of the procedure allowed us to eliminate the conversions
[10]. The major criticism of robotic-assisted laparoscopy is
the cost of the robotic platform and instruments, which
has become more of a concern with the rising costs of
health care. Addressing the issue of cost requires complex
comprehensive modeling that incorporates not only the
surgical costs but also abstract variables such as the cost of
postoperative complications and delays in return to work.
There have been several studies modeling the cost of various
surgicaltechniquesforendometrialcarcinoma.IntheUnited
States Bell et al. estimated the cost of endometrial cancer
staging to be $12,943 by laparotomy, $7569 with traditional
laparoscopy, and $8212 with robotic-assisted laparoscopy
[11], and Barnett at al. estimated the cost to be $12,847
with laparotomy, $10,128 with traditional laparoscopy, and
$11,476 with robotic-assisted laparoscopy [12]. In Canada,
patients undergoing robotics had longer operating times
(233 versus 206 minutes) but suﬀered fewer adverse events
(13% versus 42%;P<0.0001), lower estimated median
blood loss (50 versus 200mL, P<0.0001), and median
hospital stay was signiﬁcantly shorter (1 versus 5 days; P<
0.0001). The overall direct and indirect hospital costs were
signiﬁcantly lower for robotics compared to the historical
group (7644 versus 10368 CND; P<0.0001) even when
acquisitionandmaintenancecostwereincluded(8370versus
10368 CND; P = 0.0002). Within two years after surgery,
the recurrence rate was lower in the robotic group compared
to the historic cohort (P<0.0001), although more mature
data is eagerly expected [13]. When multiple cost variables
are incorporated there appears to be a cost advantage to
minimally invasive approaches.
3. SurgicalTechnique: Lymphadenectomy
versus No Lymphadenectomy versus Sentinel
Lymph Node Mapping
One of the most intense controversies in endometrial cancer
revolves around the need for lymphadenectomy at the time
of hysterectomy/BSO and the extent of lymphadenectomy
that should be performed. A majority of cases present with
clinical stage 1 disease (80%), without evidence of spread
beyond the uterine cavity on either physical examination or
radiologic imaging. However, the publication of GOG 33
in 1987 demonstrated that when complete surgical staging
is performed, 22% of patients with clinical stage I disease
have either lymph node metastases (12%), adnexal disease,
intraperitoneal spread, or positive peritoneal cytology [14].
Thisstudyalsoidentiﬁedimportantfactorspredictinglymph
node involvement including tumor grade, depth of myome-
trial invasion, and lymphvascular space invasion. Since the
publicationofthisstudy3strategiesregardinglymphadenec-
tomy have emerged. (1) Routine complete pelvic and para-
aortic lymphadenectomy for all patients, with adjuvant
treatment decisions based on the complete surgical staging.
(2) Never perform routine lymphadenectomy, with risk of
lymphnodemetastasisandrecurrencebeingestimatedbased
on uterine factors such grade, depth of invasion, LVSI, and
tumor size. (3) Selective lymphadenectomy based on the
intraoperative assessment of grade and depth of invasion.
As will be seen in the following discussion, the subsequent
studies of early-stage endometrial carcinoma have been
inﬂuenced signiﬁcantly by these diﬀerent approaches to
lymphadenectomy (Table 4).
3.1. Routine Lymphadenecomy. Following publication of
GOG 33 there was a movement towards performing a
systematic complete pelvic/para-aortic lymph node dissec-
tion in all patients with endometrial carcinoma. Potential
beneﬁts of this aggressive surgical approach include detailed
information about the extent of spread, leading to improved
understandingofprognosis,tailoredadjuvanttreatment,and
possible therapeutic beneﬁt. The prognostic value of lymph
nodestatushasbeenwelldeﬁned,with5-yearrecurrencefree
survivalof90%withnegativenodes,75%withpositivepelvic
nodes, and 40% with positive para-aortic nodes [15]. Those
who support routine systematic lymphadenectomy believe
that a negative lymphadenectomy allows for minimization
of adjuvant treatment for patients with uterine conﬁned
disease. Furthermore, by identifying positive lymph nodes
it is possible to deﬁne a group of patients who require even
more aggressive treatment such as extended ﬁeld radiation
therapy to cover the para-aortic nodes and/or systemic
chemotherapy. These potential beneﬁts must be weighted
against the unique intra/postoperative risks associated with
lymphadenectomy including longer surgical time, risk
of vascular/nerve injury, and lymphocyst/pelvic infection.
Although there have been numerous retrospective studies
indicating a therapeutic value to lymphadenectomy, several
recent randomized trials discussed below have questioned
this belief (Table 3).
3.2. No Lymphadenectomy. The least invasive lymph node
strategy which has been studied more in European centers
involvesthecompleteomissionofroutinelymphadenectomy
completely from the surgical procedure. Although, it should
be noted that most study protocols using this strategy do
recommend sampling of grossly suspicious lymph nodes.
The risk of lymph node metastasis and recurrence is then
estimated based on uterine risk factors such as grade, depth
of invasion, LVSI, tumor size, and also patient age. Decisions
regarding adjuvant treatment are then based on the degree of
risk. Proponents of this strategy feel that this will limit the
risks associated with lymphadenectomy, while still allowing
for adequate treatment of patients with high risk of lymph4 Obstetrics and Gynecology International
Table 3: Some important randomized trials comparing external beam radiation therapy to observation or vaginal brachytherapy alone.
Treatment
comparison
Local recurrence
rate 5-year OS Distant
recurrence rate G3/4 toxicity
PORTEC-1 EBRT versus
observation
4% versus 14%
(P<0.001)
81% versus 85%
(P = 0.31) 8% versus 7% 2% versus 0.002%
GOG99 EBRT versus
observation
3% versus 12%
(P = 0.007)
92% versus 86%
(P = 0.6) 5% versus 6% 5% versus 0.5%
PORTEC-2 EBRT versus vaginal
brachytherapy alone
2.1% versus 5.1%
(P = 0.17)
80% versus 85%
(P = 0.57) 6% versus 8% 2% versus <1%
EBRT—external beam radiation therapy, OS = overall survival.
Table 4: Some important studies of chemotherapy in endometrial cancer.
PFS OS Toxicity issues
RCT:GOG 122
(advanced stage)
WAR versus
chemotherapy (AP) 38% versus 50% 42% versus 55% Treatment-related
death 2% versus 4%
RCT:GOG 177
(Advanced stage)
Chemotherapy:AP
versus TAP
5.3 versus 8.3 12.3 versus 15.3 Grade 3
(months) (months) neuropathy
(P<0.01) (P = 0.037) 1% versus 12%
Phase II:RTOG
9708 (All stages)
Chemoradiation:pelvic
radiation (with
concurrent cisplatin) + 4
cycles of TP
All stages: 81%
Stage III = 72%
All stages: 85%
Stage III = 77%
Grade 3 = 16%
Grade 4 = 5%
RCT = randomizedcontrolled trial,WAI = whole-abdominalradiation,AP = doxorubicin and cisplatin,TAP = paclitaxel, doxorubicin,cisplatin(+ﬁlgrastim),
TP = paclitaxel and cisplatin, PFS = progression-free survival, and OS = overall survival.
node metastasis and high risk of recurrence. Critics point
out that without pathologic assessment of lymph node
status more patients will require adjuvant treatment, and the
chosen adjuvant treatment may be inadequate if there are
already lymphatic metastases.
The evaluation of the therapeutic value of systematic
lymphadenectomy has been addressed by two recent multi-
centered randomized controlled trials which compared lym-
phadenectomy to no lymphadenectomy. Although both did
not show any diﬀerence in survival after routine systematic
lymphadenectomy, they have been the subject of extensive
criticism [16, 17]. Benedetti-Panici et al. randomized 514
women less than age 75 with clinical stage I endometrial
cancer to systematic pelvic lymphadenectomy or no lym-
phadenectomy [18]. Inclusion to the study required frozen
section demonstrating myometrial invasion and stage IB-G1
were excluded. Para-aortic dissection was performed at the
discretion of the surgeon, and bulky nodes (>1cm) could
be removed even in the control arm. The study found no
signiﬁcant diﬀerence in 5-year disease free survival (81%
versus 82%) or 5-year overall survival (86% versus 90%)
and no diﬀerence in site or pattern of recurrence. However,
in this study the use of adjuvant treatment was left to the
discretion of the treating physician, and signiﬁcantly more
patientsinthenolymphadenectomygroupreceivedadjuvant
radiation therapy (25.2% versus 16.7%). In contrast, more
patients in the lymphadenectomy group received adjuvant
chemotherapy. It should also be noted that removal of
suspicious lymph nodes was a component of the no lym-
phadenectomy strategy, resulting in 16% of women in the no
lymphadenectomy group having >6n o d e sr e m o v e d .
The second trial was the MRC ASTEC trial which
randomized 1408 women with clinical stage I or II endome-
trial cancer to either systematic pelvic lymphadenectomy or
no lymphadenectomy [19]. Para-aortic lymphadenectomy
was left to the discretion of the surgeon, and removal
of suspicious pelvic lymph nodes was permitted in the
“no lymphadenectomy” group. Patients found to have
intermediate- and high-risk disease (IAG3, IBG3, IC-all
grades, IIA, serous/clear cell) were then randomized to
external beam pelvic radiation therapy versus no external
beam radiation as part of a combined trial with NCIC
EN.5 which examined the utility of adjuvant external
beam radiotherapy [20]. Patients found to have low-risk
early-stage or advanced disease were treated according to
physician preference. Vaginal brachytherapy was left to the
discretion of the treating physician in all patients. The study
found no diﬀerence in recurrence-free survival or overall
survival between the routine lymphadenectomy and the
“no lymphadenectomy” group. However, one must consider
that the patients we expect to help most by performing
routine lymphadenectomy are the 10% of intermediate-high
risk patients who have occult pelvic and sometimes para-
aortic lymph node metastases. This study included a large
proportion of low-risk patients (50% low risk compared
with only 37% intermediate and high risk) who would
be unlikely to beneﬁt from lymphadenectomy or adjuvant
treatment. In addition, the study randomized intermediate-
high risk patients to EBRT versus no EBRT, including those
with positive pelvic lymph nodes (Stage IIIC). Although
this group was small, the beneﬁt of nodal dissection may
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have been triaged into adjuvant therapy were randomized to
no additional treatment. The occult IIIC patients identiﬁed
by lymphadenectomy are patients for whom we hope to
ﬁnd eﬃcacious adjuvant treatment, possibly using systemic
chemotherapy. In this study 50% of these patients received
no adjuvant treatment, except possibly vaginal brachyther-
apy. Even among patients with advanced stage disease only
25% received adjuvant chemotherapy treatment. Although
there was limited standardization regarding adjuvant treat-
ment particularly in the low-risk and advanced stage disease,
all patients were included in the survival analysis. Further-
more, the limited staging requirement of only pelvic lymph
nodes neglects to identify patients who could beneﬁt from
extended ﬁeld radiation treatment or chemotherapy due
to positive para-aortic nodes. Lastly, despite randomization
in the ASTEC study the lymphadenectomy group ended
up with more high-risk patients, with 3% more poor
histology, 3% more grade 3 lesions, 3% more +LVSI, and
10% more with deep myometrial invasion. Although each
of these diﬀerences is small in magnitude, recall that the
intermediate-high risk group for whom we expect adjuvant
therapy to have the greatest inﬂuence makes up only 10–
20% of patients with endometrial cancer. Thus any possible
survival beneﬁt to routine lymphadenectomy may have been
obscured by the fact that the lymphadenectomy group were
at higher risk to start with.
These 2 recent RCTs suggest that the removal of lymph
node tissue may not have a large impact on survival. How-
ever, the design of these studies has not addressed the most
important impact of lymphadenectomy which is to identify
patients who can safely avoid adjuvant treatment and others
whowouldbeneﬁtfrommoreaggressiveadjuvanttreatment.
In the Benedetti-Panici trial the “no lymphadenectomy” arm
received signiﬁcantly more adjuvant therapy than patients
whohadcompletelymphnodestaging.Althoughcomparing
the true toxicity from lymphadenectomy and radiation
therapy is diﬃcult as both of these toxicities are likely
underreported in literature, it is possible to extract data from
someofthelargerandomizedcontrolledtrials.IntheASTEC
study there were more adverse events in the lymphadectomy
group versus no lymphadectomy with ileus (3% versus
1%), deep venous thromboembolism (1% versus 0.1%),
lymphocyst (1% versus 0.3%) and major wound dehiscence
(1%versus0.3%).However,theextrapolationoftheseresults
is questionable in the current era of minimally invasive
surgery, as only 6% of the ASTEC surgeries were performed
laparoscopically. Furthermore, among the 94% performed
by laparotomy a pfannenstiel incision was performed more
frequently for patients without lymphadenectomy compared
to with lymphadenectomy (49% versus 32%). These risks
of lymphadenectomy must be compared with the potential
complications of external beam radiation, which is required
more often in patients in who lymphadenectomy is omitted.
Radiation eﬀects include both early and late complications
such as enteritis, proctitis, cystitis, ﬁstula formation, chronic
gastrointestinal bleeding, hematuria, and diarrhea which can
aﬀect patients for their entire life [21]. Further discussion of
these potential complications is presented below.
3.3. Selective Lymphadenectomy. Another strategy consists
of performing a selective lymphadenectomy based on the
intraoperative assessment of grade and depth of invasion.
This is probably the strategy employed by many surgeons
who are not devoted to one or the other approach, as
it facilitates lymph node assessment in the patients at
highest risk of lymph node metastasis, while minimizing
operative morbidity. However, the utility of this strategy is
limited by the inaccuracy of pre/intraoperative pathology
assessment,whereupto15–25%ofG1biopsiesareupgraded
on ﬁnal pathology [22]. Furthermore, gross intraoperative
estimation of depth of invasion may be inaccurate especially
for high-grade lesions, where small nest of tumor cells
often invade deeply into the myometrium. Goﬀ and Rice
showed that for grade 3 lesions depth of invasion was only
accurately determined in 31% of cases [23]. The speciﬁc
threshold for proceeding with lymphadenectomy and the
extent oflymphadenectomy(+/−para-aortic)remainsoper-
ator dependent. An example of this strategy is the protocol
developed by the Mayo clinic in which lymphadenectomy is
omitted for patients with no invasion independent of grade,
or for patients with G1/G2 tumors with myoinvasion <50%
and primary tumor diameter <2cm. For grade 3 tumors
or for tumors invading more than 50% or larger than 2cm
an extensive dissection is performed with lymphadenectomy
extending up to the renal vessels and excision of the gondal
vessels at their insertion [24].
One of the drawbacks to the selective lymphadenectomy
strategy is the risk of inaccurate intraoperative pathology
assessment that would potentially beneﬁt from pelvic/para-
aortic lymph node dissection. The impact of this can
now be reduced because a secondary operation to remove
lymph nodes can be performed using a minimally invasive
technique with minimal morbidity.
3.4. Sentinel Lymph Node Mapping. One elegant strategy
that would resolve the controversy on lymphadenectomy
is the implementation of sentinel lymph node mapping.
This procedure is independent of the surgical approach,
and can reduce complications associated with full lym-
phadenectomy, while providing information needed to plan
adjuvant treatment. Several protocols have been examined
using injection of blue dye, Technetium 99, or both into
the cervix and/or uterine fundus [25]. Abu-Rustum et al.
used an easy reproducible cervical injection to map the
sentinel lymph nodes in grade 1 endometrial cancer and
achieved intraoperative localization in 86% of patients [26].
In cases with successful localization, all node-positive cases
were identiﬁed. A more recent French study (SENTI-ENDO)
utilizing a similar injection protocol looked at 133 patients
who underwent sentinel lymph node biopsies, followed by
complete lymphadenectomy [27]. 90% of patients had at
least one SLN detected, and of these 17% had pelvic lymph
node metastases. There were 3 patients with false-negative
SLN, but all were type II high-grade cancers with greater
than 50% invasion. SLN upstaged 10% of low-risk and 15%
of intermediate-risk patients. A recent meta-analysis found
that pericervical injection had an increased detection rate6 Obstetrics and Gynecology International
compared to hysteroscopic or subserosal injection technique
[28]. The combination of radiolabelled colloid and blue dye
was associated with the highest detection rate and lowest
false-negative rate. A national Canadian study on sentinel
lymph node mapping in endometrial cancer, led by the GOC
(Society of Gynecologic Oncology of Canada), is presently
undergoing evaluation.
4. Role of AdjuvantExternalBeam Radiation
Therapy in IntermediateHigh-Risk
Early-StageDisease
External beam pelvic radiotherapy (EBRT) has commonly
been used as adjuvant treatment for high risk endometrial
cancer. Recently, several large randomized controlled trials
have assessed the beneﬁt of adjuvant radiation treatment in
early-stagepatientswithsurgical-pathologicfeaturesindicat-
inganintermediate-and/orhigh-risk ofrecurrence.Theﬁrst
of these studies, PORTEC-1 was a multi-institutional study
in groups who did not perform routine lymphadenectomy
[29]. In the PORTEC-1 study intermediate risk patients
(G1 > 50% invasion, G2 any invasion, and G3 < 50%
invasion) were randomized after hysterectomy without lym-
phadenectomy (except biopsy of suspicious nodes) to pelvic
radiotherapy (4600cGy) versus no further therapy. Stage IC-
G3 patients were excluded, and vaginal brachytherapy was
not given. Although there was a reduction in 5-year local
recurrence rate (4% versus 14%, P<0.001), there was no
diﬀerence in 5-year overall survival (81% versus 85%, P =
0.37).AreanalysisofPORTEC-1with10yearoverallsurvival
still showed no diﬀerence (66% versus 73%, P = 0.09)
[30]. Another feature of PORTEC-1 was that 31/35 (89%)
of patients with vaginal recurrence had a complete response
to salvage therapy with a 65% 5-year survival rate.
A similar study performed by the Gynecologic Oncology
Group (GOG 99) randomized intermediate risk (IB, IC, IIA
occult, IIB occult disease) completely staged patients (pelvic
andpara-aorticLN)topelvicradiotherapy(5040cGy)versus
no further therapy [31]. As with PORTEC-1, although the 2-
year locoregional recurrence rate was lower in the radiation
group (3% versus 12%, P = 0.007), the 4-year overall
survival was not signiﬁcantly diﬀerent (92% versus 86%, P =
0.557). The distant metastasis rate was similar (5% versus
6%), and 2/3 of the local recurrences could be salvaged with
radiation therapy. In GOG99 there was a subgroup which
performed very poorly without radiation treatment (older
age, G2/G3, LVSI, and outer 3rd myometrial invasion). Both
studiesdemonstratedthatexternalbeamradiationtreatment
could reduce the risk of local regional recurrence by about
2/3, but did not improve overall survival, regardless of
whether routine lymphadenectomy was performed. Approx-
imately 2/3 of patients with local regional recurrence could
be salvaged with radiation treatment at time of recurrence.
Thus overall local-regional control is similar regardless of
adjuvant EBRT, it is just a question of whether the radiation
treatment is given adjuvantly or after local recurrence. In
both studies the radiation treatment did not seem to have
any eﬀect on the risk of distant recurrence (5-6%). Another
component of useful data from these 2 studies is assessment
of side eﬀects from radiation treatment. In GOG99 there
was signiﬁcantly more grade 3/4 toxicity in the radiation
arm (4.7% versus 0.5%), and 2 patients in the radiation arm
died from radiation-induced gastrointestinal complications.
In PORTEC 1 the toxicity was 25% in the radiation arm
versus 6% in the control arm, with 3% of patients in
the radiation arm experiencing grade 3/4 toxicity. A recent
retrospective review suggests the development of radiation
complications is accelerated after laparoscopic surgery (21
versus 45 months), but the incidence of grade 3 or 4 toxicity
was higher after laparotomy (61.1 versus 14.3%) [21].
Based on the major risk factors for recurrence in
PORTEC-1 another study (PORTEC-2) was designed to
compare EBRT with vaginal brachytherapy alone in a group
high-intermediate risk patients. High-intermediate risk was
deﬁned as age > 60 with stage IC-G1/G2, stage IB-G3, or any
age with Stage IIA, excluding IC-G3. Eligible patients were
randomized to EBRT (4600cGy) versus vaginal brachyther-
apy only [32]. There was no diﬀerence in vaginal recurrence
rate (1.6% versus 1.8%, P = 0.74) or overall survival (79.6%
versus 84.8%, P = 0.57). There was also no diﬀerence
in the rate of locoregional relapse (vaginal or pelvic) or
isolated pelvic recurrence. Vaginal brachytherapy alone was
also associated with signiﬁcantly less morbidity, with no
addedgastrointestinaltoxicity[33].Thethreestudiesshowed
that radiotherapy, whether EBRT or vaginal brachytherapy
can inﬂuence locoregional recurrence but have little eﬀecton
distant recurrence or overall survival. This observation has
shifted practice and research towards a systemic treatment
focus.
5. The Role of AdjuvantChemotherapy in
IntermediateHigh-RiskDisease
Considering the lack of survival beneﬁt from adjuvant
external beam radiation therapy and lack of eﬀect on distal
recurrencerate,therehasbeenincreasinginterestinincorpo-
rating adjuvant chemotherapy in the treatment of early-stage
intermediate-high risk patients. Patients in PORTEC1 with
stage IC-G3 disease had a ﬁve-year distant metastasis rate of
31%,andoverallsurvivalrateof58%despitereceivingEBRT.
Althoughtheimpactofchemotherapyintheadjuvantsetting
is lacking, there are several studies demonstrating the eﬀect
of chemotherapy in advanced disease. The GOG performed
a study (GOG122) for women with advanced stage endome-
trial carcinoma (Stage III/IV with postoperative residual dis-
ease) where patients were randomized to whole abdominal
radiation versus chemotherapy (doxorubicin/cisplatin) [34].
This study showed signiﬁcantly improved progression-free
and overall survival with combination chemotherapy. Stud-
iesofotherchemotherapyregimensinadvancedendometrial
cancer have resulted in the chemotherapy regimen being
examined in the current GOG249 protocol for intermediate-
high risk early-stage endometrial carcinoma: paclitaxel and
carboplatin. GOG177 compared doxorubicin/cisplatin (AP)
with a 3 drug regimen including taxol/doxorubicin/cisplatin
(TAP) [35]. This study demonstrated improved responseObstetrics and Gynecology International 7
rate, progression-free survival and overall survival with the
addition of paclitaxel but signiﬁcantly increased toxicity with
the 3-drug regimen. A current GOG study of chemotherapy
in advanced endometrial cancer (GOG 209) is comparing
the 3-drug regimen from GOG 177 (TAP) with a less toxic
regimen (paclitaxel/carboplatin). The results of this study
may signiﬁcantly inﬂuence the regimen used for adjuvant
treatment in early-stage high-risk disease. RTOG 9708 was
a Phase II study for high-risk endometrial carcinoma in
which 46 patients with G2/G3 lesions, greater than 50%
invasion, cervical stromal invasion (IIB), or pelvic-conﬁned
extrauterine disease were treated with whole pelvic radiation
with concurrent cisplatin chemotherapy sensitization, then
followed by 4 cycles of taxol/cisplatin chemotherapy [36].
Although this was not a randomized controlled trail, the
results are intruiging. In the stage IC, IIA, IIB patients
there were no recurrences. More impressively in Stage III
patients (n = 27) the 4-year disease-free survival was
72% and overall survival was 77%, which is signiﬁcantly
better than previous studies. The concept of combining
radiation treatment with systemic chemotherapy as adjuvant
treatment for intermediate-high risk early-stage disease is
prevalent in both USA and European studies. As discussed
the current GOG 249 study is randomizing women to
either EBRT or a combination of vaginal brachytherapy
and chemotherapy (Paclitaxel/Carboplatin). PORTEC III is
also investigating this concept by randomizing high-risk
Stage I,II, IIIA, IIIC patients to pelvic radiation alone versus
pelvic radiation (with concurrent cisplatin) followed by
carboplatin/paclitaxel chemotherapy.
6. Conclusions
Although there continues to be controversy regarding
treatment of early-stage endometrial cancer, considerable
progress has been made over the past several decades.
Advancement in minimally invasive surgical techniques has
allowed extensive staging procedures to be performed with
signiﬁcantly reduced patient morbidity. Although radiation
therapy does not reduce overall survival, it does reduce the
risk of locoregional recurrence. However, for most patients
the use of vaginal brachytherapy alone can facilitate this
localized beneﬁt while minimizing long-term morbidity.
Using surgical staging it is possible to avoid unnecessary
adjuvant treatment in low-risk patients, while deﬁning a
group of higher risk early-stage patients who may beneﬁt
from more aggressive adjuvant therapy, such as systemic
chemotherapy. Hopefully the result of currently enrolling
randomized trials will further elucidate the most eﬃcacious
therapy for these high-risk patients.
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